For Research Use Only. Not for use in diagnostic procedures.

This assay has high sensitivity and excellent specificity for detection of CYP1B1. No significant cross-reactivity or interference between CYP1B1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between CYP1B1 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

We suggest pre-experimenting with neat (undiluted) samples, 1:2 or 1:4 dilutions. Please avoid diluting your samples more than 1:10 as it would exceed the dilution limit set for this kit. If the expected concentration of the target is beyond the detection range of the kit, please contact our technical support team

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of CYP1B1 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS7248093 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Cytochrome P450 1B1 (CYP1B1) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing CYP1B1. The ELISA analytical biochemical technique of the MBS7248093 kit is based on CYP1B1 antibody-CYP1B1 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect CYP1B1 antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, CYP1B1. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

Intended Uses: This CYP1B1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human CYP1B1. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Principle of the Assay: CYP1B1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-CYP1B1 antibody and an CYP1B1-HRP conjugate. The assay sample and buffer are incubated together with CYP1B1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the CYP1B1 concentration since CYP1B1 from samples and CYP1B1-HRP conjugate compete for the anti-CYP1B1 antibody . Since the number of sites is limited, as more sites are occupied by CYP1B1 from the sample, fewer sites are left to bind CYP1B1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The CYP1B1 concentration in each sample is interpolated from this standard curve.

60,846 Da

cytochrome P450, family 1, subfamily B, polypeptide 1

cytochrome P450 1B1; microsomal monooxygenase; xenobiotic monooxygenase; aryl hydrocarbon hydroxylase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile)

Cytochrome P450 1B1

CP1B1_HUMAN

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The enzyme encoded by this gene localizes to the endoplasmic reticulum and metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-estradiol. Mutations in this gene have been associated with primary congenital glaucoma; therefore it is thought that the enzyme also metabolizes a signaling molecule involved in eye development, possibly a steroid. [provided by RefSeq, Jul 2008]

CYP1B1: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Defects in CYP1B1 are the cause of primary congenital glaucoma type 3A (GLC3A). GLC3A is an autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor. Defects in CYP1B1 are a cause of primary open angle glaucoma (POAG). POAG is a complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. The disease is asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes. Defects in CYP1B1 are a cause of Peters anomaly (PAN). Peters anomaly is a congenital defect of the anterior chamber of the eye. Belongs to the cytochrome P450 family.

Protein type: EC 1.14.14.1; Oxidoreductase; Amino Acid Metabolism - tryptophan; Xenobiotic Metabolism - metabolism by cytochrome P450

Chromosomal Location of Human Ortholog: 2p22.2

Cellular Component: endoplasmic reticulum membrane; mitochondrion

Molecular Function: iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; heme binding; oxygen binding; monooxygenase activity

Biological Process: steroid metabolic process; estrogen metabolic process; collagen fibril organization; retinal metabolic process; positive regulation of apoptosis; response to toxin; positive regulation of JAK-STAT cascade; negative regulation of cell proliferation; visual perception; retinol metabolic process; arachidonic acid metabolic process; angiogenesis; cell adhesion; nitric oxide biosynthetic process; negative regulation of cell adhesion mediated by integrin; negative regulation of cell migration; epoxygenase P450 pathway; positive regulation of angiogenesis; inhibition of NF-kappaB transcription factor; toxin metabolic process; xenobiotic metabolic process; blood vessel morphogenesis; endothelial cell migration; aromatic compound metabolic process; membrane lipid catabolic process; induction of apoptosis by oxidative stress; sterol metabolic process

Disease: Peters Anomaly; Glaucoma 3, Primary Congenital, A; Glaucoma 3, Primary Infantile, B

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.